Competition to preoccupy Viread generic market of KRW 150 billion

It’s Viread for now. After Baraclude generics, domestic pharmaceutical companies are directly aiming for Viread whose substance patent is expiring soon on November next year.

Viread is a product which become the largest product after taking over the Baraclude’s 7-year throne as a hepatitis B treatment. It is looking forward to seeing annual KRW 150 billion sales since recording KRW 72.3 billio...